Study on Kawasaki disease with macrophage activation syndrome
Part of Blood & lymphatic, Heart & circulation, Immune system & allergy, Skin clinical trials.
This study is for children diagnosed with Kawasaki disease who also develop macrophage activation syndrome (a serious immune complication) within the first month. It aims to better understand and manage this combination.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child is between 1 month and under 18 years old when diagnosed with Kawasaki disease.
- Kawasaki disease was diagnosed using the 2024 AHA guidelines (your doctor will know this).
- Macrophage activation syndrome was diagnosed by the doctor within 30 days of Kawasaki disease starting.
- There is no other condition that mimics Kawasaki disease.
- Your child does not have a genetic form of hemophagocytic lymphohistiocytosis (a similar immune condition).
- You or your child can provide informed consent to join the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at certain genes (called HERVs) in children with new inflammatory conditions like Kawasaki disease, COVID-19, or other infections. It aims to learn more about how these genes might be involved in the body's response to illness.
This study looks at children with Kawasaki disease, a condition that causes inflammation in blood vessels. The goal is to learn more about how it affects kids in Europe and North India.
This trial is testing a way to match children with Kawasaki disease to the best treatment. It looks at specific symptoms and fever duration to see if a child qualifies for the study, which may help doctors give the right treatment faster.
This study uses heart imaging to better understand Kawasaki disease. It may help doctors assess heart health in affected children and teenagers.
This study tests whether an artificial intelligence program can help doctors spot Kawasaki disease earlier by looking at chest X-rays. It compares kids with Kawasaki disease to those with fever from other causes.
This trial tests whether a cholesterol-lowering medication called atorvastatin can help children whose hearts were damaged by Kawasaki disease (a serious childhood illness that inflames blood vessels). The study may help reduce long-term heart complications.
Hear when a new Kawasaki Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.